Abstract
Purpose :
To evaluate the duration of effect in photopic distance-corrected intermediate visual acuity (DCIVA) in presbyopia study participants treated with AGN-190584 on Days 1 and 30.
Methods :
The durations of attainment of ≥3-line, ≥2-line, and ≥1-line improvement in photopic DCIVA were calculated in participants who received AGN-190584 bilaterally, once daily for 30 days (n=375). Intermediate visual acuity was assessed at a distance of 66 cm (26 in).
Results :
On Day 30, the median final time point of sustained gains in photopic DCIVA was Hour 7 for a ≥3-line gain, Hour 8 for a ≥2-line gain, and beyond the 10-hour study visit duration for a ≥1-line gain in participants who achieved ≥3-line, ≥2-line, and ≥1-line gains, respectively (Figure). 96 study participants in the active treatment group achieved at least a 3-line gain, 205 at least a 2-line gain, and 312 at least a 1-line gain. On Day 1, the median final time point of sustained gains in photopic DCIVA was Hour 5 for a ≥3-line gain, Hour 7 for a ≥2-line gain, and beyond the 10-hour study visit duration for a ≥1-line gain in participants who achieved ≥3-line, ≥2-line, and ≥1-line gains respectively. 60 study participants in the active treatment group achieved at least a 3-line gain, 158 at least a 2-line gain, and 300 at least a 1-line gain.
Conclusions :
In photopic illumination conditions, participants treated with AGN-190584 obtained ≥3-, ≥2-, and ≥1-line gains in DCIVA over the course of the 10-hour study visit on Days 1 and 30.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.